成立十年无产品、累亏超23亿元，亦诺微赴港IPO解困

Core Viewpoint - Yinuo Micro is seeking to go public in Hong Kong to overcome financial challenges, despite having no commercialized products and facing significant losses and competition in the oncolytic immunotherapy market [1][8]. Financial Performance - Yinuo Micro has reported total revenues of RMB 6.772 million, RMB 3.2 million, and RMB 1.305 million for the years ending December 31, 2023, and September 30, 2024, respectively [2]. - The company has incurred substantial losses, with pre-tax losses of RMB 481.753 million, RMB 523.755 million, and RMB 337.910 million for the same periods [2][3]. - Cumulative losses have exceeded RMB 2.371 billion as of September 30, 2025, with a net current liability of RMB 2.19 billion and cash reserves of only RMB 68.594 million [3][4]. IPO Strategy - To facilitate the IPO process, Yinuo Micro has adjusted the redemption rights of its preferred shares, which will automatically become void upon the submission of the IPO application [5]. - The company has completed seven rounds of financing, raising over RMB 1 billion, but still faces pressure to complete the IPO to ensure operational continuity [4][8]. Product Pipeline and Market Challenges - Yinuo Micro's core product, MVR-T3011, is currently in Phase II clinical trials, targeting various solid tumors [6]. - The global market for oncolytic immunotherapy is projected to be only USD 8.71 million in 2024, indicating limited market potential [7]. - The company faces intense competition, with 18 oncolytic immunotherapy drugs in clinical trials globally, and at least six new therapies expected to be approved in China between 2025 and 2033 [7]. Operational and Strategic Considerations - Yinuo Micro has a small workforce of 86 employees, with plans to expand its team to support clinical and commercial development [7]. - The IPO is seen as a critical move for survival, providing necessary funding for clinical advancements and enhancing the company's credibility in the industry [8].